Despite his historic wariness of the pharmaceutical industry, Robert F. Kennedy Jr.’s stance toward weight-loss drugs appears to be softening. In December 2024, President Donald Trump’s nominee to lead the Department of Health and Human Services asserted that GLP-1 medications such as Ozempic and Mounjaro “have a place” in treating obesity. In his recent Senate […]. Read More in Red Pill NOWlej.
